R-Pharm
АО Р-Фарм · joint-stock company
R-Pharm is an international pharmaceutical company headquartered in Russia. It reached the headlines in September 2020 following approval of its drug "Coronavir" as a treatment in cases of mild to moderate COVID-19 infection. It was founded by Alexey Repik in 2001, but has had an increasingly international operations base since, with Japanese Corporation Mitsui & Co., Ltd. acquiring 10% of its shares in 2017. In 2022, against the background of the introduction of personal sanctions, Alexey Repik resigned from the owners of R-Pharm, selling his share in the company to the management of R-Pharm, and resigned as chairman of the board of directors.
Source: Wikipedia · CC BY-SA 4.0
last observed
Activity Score
0
confidence 65 % · metrics-v1
Hiring Momentum 30d
—
not enough monitored evidence
Product Velocity
0
confidence 70 % · metrics-v1
AI Adoption
0
confidence 60 % · metrics-v1
Corporate Change Index
0
confidence 85 % · cci-v1
11 active sensors·3 observations·0 historical changes·0 structured events·historical coverage 100 %·observed since 2026-09-13
Compare R-Pharm with peers on activity, hiring, product velocity, AI adoption, locations and events.
Compare companies